Amphastar P (AMPH)

Pretax margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	169,378	169,741	128,927	119,317	114,863	100,614	114,415	104,880	82,746	48,569	18,539	4,910	4,943	11,571	7,275	69,502	62,662	63,995	65,434	-726
Revenue (ttm)	US$ in thousands	644,395	601,313	540,886	518,641	498,987	484,851	476,920	455,116	437,768	412,802	384,035	368,178	349,846	337,308	334,014	327,255	322,357	328,664	324,070	316,063
Pretax margin		26.28%	28.23%	23.84%	23.01%	23.02%	20.75%	23.99%	23.04%	18.90%	11.77%	4.83%	1.33%	1.41%	3.43%	2.18%	21.24%	19.44%	19.47%	20.19%	-0.23%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $169,378K ÷ $644,395K
= 26.28%

Amphastar Pharmaceuticals Inc has displayed varying pretax margins over the past eight quarters, with fluctuations observed in its profitability before accounting for taxes. In Q3 2023, the company achieved the highest pretax margin of 28.23%, indicating strong operational efficiency and cost management. However, in Q2 2023, the pretax margin dipped to 23.84%, potentially signaling a decrease in profitability compared to the previous quarter. Despite these fluctuations, the company's pretax margins have generally been within the range of 20% to 28% over the analyzed period, reflecting a consistent performance in generating profits before tax expenses.